Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

Expert Opinion on Investigational Drugs

Volumn 11, Issue 6, 2002, Pages 737-745

  Bilodeau, Mark T ^a   Fraley, Mark E ^a   Hartman, George D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiogenesis; Flk 1; Kinase insert domain containing receptor; Vascular endothelial growth factor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MIDOSTAURIN; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; ENDOTHELIAL CELL GROWTH FACTOR; ENZYME INHIBITOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG USE; FATIGUE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LIVER TOXICITY; METABOLIC DISORDER; MOUSE; NAUSEA; NONHUMAN; PHLEBITIS; RASH; RAT; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR GROWTH; URINE COLOR; VOMITING; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMAL; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; HUMAN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; ANIMALS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036269854     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.6.737     Document Type: Review

References (68)

1. Dormancy of micro-metastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
2. Angiogenesis and tumor metastasis
3. New paradigms for the treatment of cancer: The role of anti-angiogenic agents
4. Expression of vascular endothelial growth factor and its receptor, kdr, correlates with vascularity, metastasis, and proliferation of human colon cancer
5. Anti-angiogenesis: New concept for therapy of solid tumors
6. Is angiogenesis inhibition the holy grail of cancer therapy?
7. Pituitary follicular cells create a novel heparin-binding growth factor specific for endothelial cells
8. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
9. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
10. Vascular endothelial growth factor, a potent and selective angiogenic agent
11. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
12. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
13. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
14. Vascular endothelial growth factor (VEGF-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival and resistance to chemotherapy
15. Molecular and biological properties of vascular endothelial growth factor
16. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
17. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
18. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor
19. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues
20. The angiogenic pathway 'vascular endothelial growth factor/Flk-1 (KDR)-receptor' in rheumatoid arthritis and osteoarthritis
21. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment endothelial cells
22. The role of VEGF and thrombospondin in skin angiogenesis
23. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain
24. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome
25. Synthesis and biological evaluation of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
26. Development of SU-5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
27. SU-5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
28. Indolinone tyrosine kinase inhibitors block kit activation and growth of small cell lung cancer cells
29. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU-5416
30. The angiogenesis inhibitor SU-5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
31. Pharmacokinetics of SU-5416, an anti-angiogenesis agent, after single and multiple dosing in rats and dogs
32. Pharmacokinetics and pharmacodynamics of SU-5416 in a phase I, dose escalating trial in patients with advanced malignancies
33. In vitro model to elucidate the potential of the receptor tyrosine kinase (RTK) inhibitor SU-5416 to induce CYP1A1
34. Phase I dose-escalating trial of SU-5416, a novel angiogenesis inhibitor in patients with advanced malignancies
35. Phase I trial of the VEGF inhibitor SU-5416, incorporating dynamic contrast MRI assessment of vascular permeability
36. Results of a phase I dose-escalating study of the anti-angiogenic agent SU-5416 in patients with advanced malignancies
37. A multicenter dose-escalating study of SU-5416 in AIDS-related Kaposi's sarcoma
38. SU-5416 in malignant mesothelioma: University of Chicago Phase II consortium study
39. A Phase II study with SU-5416 in patients with C-Kit positive AML
40. A Phase I/II trial and pharmacokinetic (PK) study of SU-5416 in combination with paclitaxel/carboplatin
41. A Phase I pharmacokinetic and pharmacodynamic study of SU-5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC)
42. Efficacy results of a Phase I/II study of SU-5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (pts) from a Phase III study of irinotecan (C)/F/L or F/L alone previously untreated metastatic colorectal cancer (MCRC)
43. Phase I/II study of SU-5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer
44. SU-6668 is a potent antiangiogenic and antitum or agent that induces regression of established tumors
45. The antiangiogenic protein kinase inhibitors SU-5416 and SU-6668 inhibit the SCF receptor (C-Kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
46. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms
47. SU-6668 is a potent, broad spectrum angiogenesis inhibitor that exhibits anti-tumor properties
48. SU-5416 and SU-6668: Comparative differences in toxicity profile in rats following intravenous administration
49. Phase I experience with SU-6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
50. Tyrosine kinase inhibitors: From rational design to clinical trials
51. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
52. PTK-787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
53. A Phase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF receptor-inhibitor PTK-787/ZK-222584 (PTK/ZK) in patients with liver metastasis of advanced cancer
54. Effects of PTK-787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
55. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK-787/ZK-222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases
56. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
57. Dynamic contrast enhanced magnetic resonance imaging as a surrogate marker of efficacy in a Phase I trial of a VEGF receptor tyrosine kinase inhibitor
58. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
59. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
60. Phase I and pharmacokinetic study of PKC-412, an inhibitor of protein kinase C
61. Dramatic inhibition of retinal and choroidal neovascularization of oral administration of a kinase inhibitor
62. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
63. ZD-4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
64. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
65. A Phase I study of ZD-6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors
66. Chronic and acute effects of ZD-6474, a VEGF receptor tyrosine kinase inhibitor, on established human tumour xenografts
67. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance
68. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries